Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
CT-1578
print preview
bookmark
share with colleague
General Information
Company
Cell Therapeutics Inc.
Description
Janus kinase-2 (JAK-2) inhibitor and has activity against FMS-like tyrosine kinase 3 (FLT3; CD135) and colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)
Molecular Target
Janus kinase-2 (JAK-2)
Mechanism of Action
Latest Stage of Development
Preclinical
Indication
Rheumatoid arthritis (RA)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy